Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Retained Earnings (2016 - 2025)

Capricor Therapeutics has reported Retained Earnings over the past 15 years, most recently at $283154.0 for Q4 2025.

  • Quarterly results put Retained Earnings at $283154.0 for Q4 2025, down 72.43% from a year ago — trailing twelve months through Dec 2025 was $283154.0 (down 72.43% YoY), and the annual figure for FY2025 was $283154.0, down 72.43%.
  • Retained Earnings for Q4 2025 was $283154.0 at Capricor Therapeutics, up from -$274.7 million in the prior quarter.
  • Over the last five years, Retained Earnings for CAPR hit a ceiling of $1.0 million in Q4 2024 and a floor of -$274.7 million in Q3 2025.
  • Median Retained Earnings over the past 5 years was -$126.5 million (2022), compared with a mean of -$112.1 million.
  • Biggest five-year swings in Retained Earnings: crashed 666830.86% in 2023 and later soared 100.64% in 2024.
  • Capricor Therapeutics' Retained Earnings stood at -$101.9 million in 2021, then tumbled by 34.56% to -$137.1 million in 2022, then dropped by 16.26% to -$159.4 million in 2023, then soared by 100.64% to $1.0 million in 2024, then plummeted by 72.43% to $283154.0 in 2025.
  • The last three reported values for Retained Earnings were $283154.0 (Q4 2025), -$274.7 million (Q3 2025), and -$250.1 million (Q2 2025) per Business Quant data.